Table 4.
Pathology characteristics | FNa PZb (n=73) | FN TZc (n=29) | P value |
---|---|---|---|
Biopsy Gleason, | 0.595 | ||
3 +3, | 26 (35.6%) | 13 (44.8%) | |
3+4, | 30 (41.1%) | 12 (41.4%) | |
4+3, | 4 (5.5%) | 2 (6.9%) | |
Others | 13 (17.8%) | 2 (6.9%) | |
Pathology tumor diameter (cm), median (IQRd) | 1.40 (0.80–2.00) | 1.60 (1.05–2.60) | 0.176 |
Pathology prostate weight (gm), median (IQR) | 49.5 (36.3–71.8) | 41.9 (32.6–61) | 0.222 |
Pathology Gleason score | 0.298 | ||
3 +3, | 19 (26%) | 9 (31%) | |
3+4, | 41 (56.2%) | 15 (51.7%) | |
4+3, | 7 (9.6%) | 5 (17.2%) | |
Others, | 6 (8.2%) | 0 (0%) | |
Pathology Staging | 0.488 | ||
2, | 66 (90.4%) | 25 (86.2%) | |
3a, | 7 (9.6%) | 4 (13.8%) | |
3b, | 0 (0%) | 0 (0%) | |
mpMRI characteristics | FPe PZ (n=72) | FP TZ (n=38) | P value |
Prostate volume (cm3), median (IQR) | 37.0 (30.4–48.9) | 49.8 (35.0–62.9) | 0.021 |
MRIf tumor volume (cm3), median (IQR) | 0.18 (0.07–0.40) | 0.23 (0.09–0.38) | 0.519 |
PI-RADSv2g category | 0.033 | ||
2, | 13 (18.1%) | 15 (39.5%) | |
3, | 34 (47.2%) | 18 (47.4%) | |
4, | 20 (27.8%) | 4 (10.5%) | |
5, | 5 (6.9%) | 1 (2.6%) |
False Negative,
Peripheral Zone,
Transition Zone,
Interquartile Range,
False Positive,
Magnetic Resonance Imaging,
Prostate Imaging – Reporting and Data System version 2